
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is anticipated to experience robust growth, with royalty-based income projected to enhance revenues by over 20% annually through 2026 and beyond, driven by successful commercial sales of products like Vabysmo and new launches such as Ojemda and Miplyffa. The company's total income soared to $28.5 million in 2024 from $4.8 million in 2023, reflecting significant increases in revenues attributed to both purchased receivables and customer contracts. Furthermore, XOMA is expected to generate revenues of $49.0 million in 2026, marking a 36% rise compared to 2025, underpinned by contributions from earlier-stage assets and milestone payments resulting from ongoing clinical progress.
Bears say
XOMA Royalty Corp has demonstrated variability in revenues and net earnings as a result of its participation in the international market, exposing the company to risks associated with economic downturns and changes in governmental policies, which could negatively impact operational performance. Additionally, challenges such as failed clinical trials and the potential loss of key executives may hinder the company’s ability to secure adequate funding and maintain necessary industry expertise. Finally, recent declines in share performance reflect broader market issues in the biotechnology sector, further exacerbating the negative sentiment surrounding XOMA's financial stability and growth prospects.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares